Stage-specific effect of nodal metastases on survival in patients with non-metastatic renal cell carcinoma

BJU International

Volumn 103, Issue 1, 2009, Pages 33-37

  Capitanio, Umberto ^a   Jeldres, Claudio ^a   Patard, Jean Jacques ^b   Perrotte, Paul ^c   Zini, Laurent ^a   De La Taille, Alexandre ^d   Ficarra, Vincenzo ^e   Cindolo, Luca ^f   Bensalah, Karim ^b   Artibani, Walter ^g   Tostain, Jacques ^h   Valeri, Antoine ⁱ   Zigeuner, Richard ^j   Méjean, Arnaud ^j   Descotes, Jean Luc ^k   Lechevallier, Eric ^l   Mulders, Peter F ^m   Lang, Herve ^m   Jacqmin, Didier ⁿ   Karakiewicz, Pierre I ^a,c  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^b RENNES UNIVERSITY HOSPITAL   (France)

^c UNIVERSITÉ DE MONTRÉAL   (Canada)

^d HENRI MONDOR HOSPITAL   (France)

^e UNIVERSITY OF PADOVA   (Italy)

^f G RUMMO HOSPITAL   (Italy)

^g UNIVERSITÉ JEAN MONNET   (France)

^h BREST UNIVERSITY HOSPITAL   (France)

ⁱ MEDICAL UNIVERSITY OF GRAZ   (Austria)

^j Necker Medical School   (France)

^k GRENOBLE UNIVERSITY HOSPITAL   (France)

^l ASSISTANCE PUBLIQUE HÔPITAUX DE MARSEILLE   (France)

^m RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

ⁿ UNIVERSITY HOSPITAL OF STRASBOURG   (France)

more..

Author keywords

Cause specific survival; Lymph node invasion; Radical nephrectomy; Renal cell carcinoma

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER GRADING; CANCER MORTALITY; CANCER STAGING; CANCER SURVIVAL; CAUSE SPECIFIC SURVIVAL; CHILD; FEMALE; HUMAN; HUMAN TISSUE; KIDNEY CARCINOMA; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NEPHRECTOMY; PARTIAL NEPHRECTOMY; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; SCHOOL CHILD; UNIVARIATE ANALYSIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, RENAL CELL; CHILD; EPIDEMIOLOGIC METHODS; FEMALE; HUMANS; KIDNEY NEOPLASMS; LYMPH NODE EXCISION; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM STAGING; NEPHRECTOMY; PROGNOSIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 57649153172     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2008.08014.x     Document Type: Article

References (30)

1. Antonelli A, Cozzoli A, Zani D et al. The follow-up management of non-metastatic renal cell carcinoma: definition of a surveillance protocol. BJU Int 2007 99 : 296 300
2. Klatte T, Wunderlich H, Patard JJ et al. Clinicopathological features and prognosis of synchronous bilateral renal cell carcinoma: an international multicentre experience. BJU Int 2007 100 : 21 5
3. Verhoest G, Veillard D, Guille F et al. Relationship between age at diagnosis and clinicopathologic features of renal cell carcinoma. Eur Urol 2007 51 : 1298 304
4. Terrone C, Cracco C, Porpiglia F et al. Reassessing the current TNM lymph node staging for renal cell carcinoma. Eur Urol 2006 49 : 324 31
5. Patard JJ. Prognostic and biological significance of lymph node spreading in renal cell carcinoma. Eur Urol 2006 49 : 220 2
6. Ficarra V, Novara G, Iafrate M et al. Proposal for reclassification of the TNM staging system in patients with locally advanced (pT3-4) renal cell carcinoma according to the cancer-related outcome. Eur Urol 2007 51 : 722 9
7. Margulis V, Tamboli P, Jacobsohn KM, Swanson DA, Wood CG. Oncological efficacy and safety of nephron-sparing surgery for selected patients with locally advanced renal cell carcinoma. BJU Int 2007 100 : 1235 9
8. Bandi G, Christian MW, Hedican SP, Moon TD, Nakada SY. Oncological outcomes of hand-assisted laparoscopic radical nephrectomy for clinically localized renal cell carcinoma: a single-institution study with > or ≥3 years of follow-up. BJU Int 2008 101 : 459 62
9. Hutterer GC, Patard JJ, Perrotte P et al. Patients with renal cell carcinoma nodal metastases can be accurately identified: external validation of a new nomogram. Int J Cancer 2007 121 : 2556 61
10. Van Poppel H, Da Pozzo L, Albrecht W et al. A prospective randomized EORTC intergroup phase 3 study comparing the complications of elective nephron-sparing surgery and radical nephrectomy for low-stage renal cell carcinoma. Eur Urol 2007 51 : 1606 15
11. Blom JH, van Poppel H, Marechal JM et al. Radical nephrectomy with and without lymph node dissection: preliminary results of the EORTC randomized phase III protocol 30881 EORTC Genitourinary Group. Eur Urol 1999 36 : 570 5
12. Ljungberg B, Hanbury DC, Kuczyk MA et al. Renal cell carcinoma guideline. Eur Urol 2007 51 : 1502 10
13. Somani BK, Nabi G, Thorpe P, N'Dow J, Swami S, McClinton S. Image-guided biopsy-diagnosed renal cell carcinoma: critical appraisal of technique and long-term follow-up. Eur Urol 2007 51 : 1289 95
14. Karakiewicz PI, Lewinshtein DJ, Chun FK et al. Tumor size improves the accuracy of TNM predictions in patients with renal cancer. Eur Urol 2006 50 : 521 8
15. Patard JJ, Leray E, Rioux-Leclercq N et al. Prognostic value of histologic subtypes in renal cell carcinoma: a multicenter experience. J Clin Oncol 2005 23 : 2763 71
16. Karakiewicz PI, Briganti A, Chun FK et al. Multi-institutional validation of a new renal cancer-specific survival nomogram. J Clin Oncol 2007 25 : 1316 22
17. Rioux-Leclercq N, Karakiewicz PI, Trinh QD et al. Prognostic ability of simplified nuclear grading of renal cell carcinoma. Cancer 2007 109 : 868 74
18. Canfield SE, Kamat AM, Sanchez-Ortiz RF, Detry M, Swanson DA, Wood CG. Renal cell carcinoma with nodal metastases in the absence of distant metastatic disease (clinical stage TxN1-2M0): the impact of aggressive surgical resection on patient outcome. J Urol 2006 175 : 864 9
19. Karakiewicz PI, Trinh QD, Bhojani N et al. Renal cell carcinoma with nodal metastases in the absence of distant metastatic disease: prognostic indicators of disease-specific survival. Eur Urol 2007 51 : 1616 24
20. Messing EM. Node positive renal cell cancer. Who can be helped? Eur Urol 2007 51 : 1477 8
21. Ficarra V, Artibani W. Staging system of renal cell carcinoma: current issues. Eur Urol 2006 49 : 223 5
22. Motzer RJ, Rini BI, Bukowski RM et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 2006 295 : 2516 24
23. Escudier B, Eisen T, Stadler WM et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007 356 : 125 34
24. Patard JJ, Rioux-Leclercq N, Fergelot P. Understanding the importance of smart drugs in renal cell carcinoma. Eur Urol 2006 49 : 633 43
25. Kirkali Z, Van Poppel H. A critical analysis of surgery for kidney cancer with vena cava invasion. Eur Urol 2007 52 : 658 62
26. Sciarra A, Gomez AM, Gentilucci A et al. Adjuvant therapy with sorafenib in bone metastases bilateral renal carcinoma: a case report. Eur Urol 2007 52 : 597 9
27. Karakiewicz P, Perrotte P, Trinh QD, Patard JJ. Rebuttal from authors re: Edward M. Messing. Node positive renal cell cancer. Who can be helped? Eur Urol 2007 51 : 1478 80
28. Berntsen A, Geertsen PF, Svane IM. Therapeutic dendritic cell vaccination of patients with renal cell carcinoma. Eur Urol 2006 50 : 34 43
29. Skolarikos A, Alivizatos G, Laguna P, de la Rosette J. A review on follow-up strategies for renal cell carcinoma after nephrectomy. Eur Urol 2007 51 : 1490 500
30. Terrone C, Volpe A. The role of pathology for clinical decision-making in renal cell carcinoma is increasing. Eur Urol 2007 51 : 1166 8